LB-100 for low-risk MDS after prior treatment failure
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 1/2 trial studies LB-100 in adults with low or intermediate-1 risk myelodysplastic syndromes (MDS). It may help by improving blood counts or disease control in people whose prior treatments have not worked or stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent and follow study instructions.
- You are 18 or older.
- You have confirmed low or intermediate-1 risk MDS (or MDS/MPN) that needs treatment because of low blood counts.
- Your kidneys and liver labs are adequate (kidney clearance ≥60, and liver enzymes below 3× the usual limit).
- Your heart tests are acceptable and your performance status (energy/function) is 0–2.
- If you had the non-5q or del(5q) form, you must have tried specific prior drugs and not responded or lost response.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
This trial tests a new drug called LP-108 combined with azacitidine for people with certain blood cancers like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It aims to see if the combination is safe and helps shrink or control the cancer.
This trial tests an experimental drug called BL-M11D1 for people with myelodysplastic syndromes (MDS) that has come back or not improved with standard treatment. The drug targets a protein called CD33 on cancer cells and may help reduce the number of abnormal cells in the bone marrow.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.